Winton Group’s Heron Therapeutics HRTX Stock Holding History

Winton Group’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-13,621	Closed	-$288K	–	1403
2020 Q4	$288K	Sell	13,621 -55,990	-80%	-$973K	0.02%	1064
2020 Q3	$1.03M	Sell	69,611 -51,579	-43%	-$805K	0.03%	814
2020 Q2	$1.78M	Buy	121,190 +43,746	+56%	+$719K	0.05%	709
2020 Q1	$909K	Buy	77,444 +21,577	+39%	+$406K	0.02%	843
2019 Q4	$1.31M	Buy	55,867 +26,769	+92%	+$592K	0.02%	960
2019 Q3	$538K	Buy	+29,098	New	+$536K	0.01%	1061
2019 Q2	–	Sell	-8,724	Closed	-$213K	–	1201
2019 Q1	$213K	Buy	+8,724	New	+$228K	﹤0.01%	942

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Winton Group's HRTX Position: Q1 2021 in Review

Winton Group sold out of Heron Therapeutics (HRTX) in Q1 2021, closing a stake of 13,621 shares — an estimated $288K sold.

Winton Group first reported a position in HRTX in Q1 2019 and held it in 7 quarters. The position peaked at $1.78M in Q2 2020. 193 funds tracked by Wall St. Rank hold HRTX as of Q1 2021.

Winton Group reported no remaining Heron Therapeutics position as of Q1 2021 after selling out during the quarter.
Winton Group sold 13,621 Heron Therapeutics shares in Q1 2021, an estimated $288K.
Winton Group first reported a position in Heron Therapeutics in Q1 2019 and held it in 7 quarters.
Winton Group's Heron Therapeutics position peaked at $1.78M in Q2 2020.
193 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2021.

Based on Winton Group's 13F filing for Q1 2021, filed 21 Jul 2021.